MDK: A Target Enabling Package
Creators
- 1. Department of Pharmacology and Chemical Biology, Emory University, Atlanta, USA.
- 2. Alzheimer's Research UK Oxford Drug Discovery Institute, Centre for Medicines Discovery, University of Oxford, Oxford, United Kingdom
-
3.
Emory University
- 4. Center for Neurodegenerative Disease, Department of Neurology, Emory University, Atlanta, USA.
-
5.
Sage Bionetworks
-
6.
Jackson Laboratory
Description
Midkine (MDK) is a secreted heparan-sulfate binding cytokine and plays many roles in the development of disease pathology, particularly in neurodegeneration. It binds cell surface proteoglycans receptors via their chondroitin sulfate groups and its expression is regulated by retinoic acid. The roles of MDK are regulated by its interaction with heparan sulfate proteoglycans on the cell surface. From a pathological standpoint, proteomic analysis has shown it to be co-expressed with other amyloidogenic proteins, in addition to being highly colocalized in amyloid-beta plaques (2). The aim of this TEP is to generate reagents useful for investigating the role of MDK in Alzheimer’s disease, such as validation of available antibodies, generic knockout/knockdown cell lines and purified protein.
Notes
Future versions of this TEP will contain experimental data on the Midkine TEP.
Files
TREAT-AD Basic TEP_MDK_v2_Final.pdf
Files
(1.5 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:738716daf5ae91375fa7d5d599671306
|
1.5 MB | Preview Download |